



Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting

Presentations highlight activity against MRSA and drug-resistant strains

San Diego, CA, September 12, 2009 – Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of torezolid at the low 200 mg dose against methicillin-sensitive and methicillin-resistant bacteria in patients with severe complicated skin and skin structure infections (cSSSI). *In vitro* studies presented at ICAAC highlight the potency of torezolid against linezolid-resistant MRSA and *cfr*-mediated resistant bacteria.

“The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid,” said Philippe Prokocimer, M.D., chief medical officer at Trius. “There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways.”

ICAAC data presentations are as follows:

Saturday, September 12

(Poster Session 024, 11:30 am – 1:30 pm)

- L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)

(Poster Session 004, 11:30 am – 1:30 pm)

- B-050/52: Comparative Efficacy of TR-701, Vancomycin (Vanco), and Daptomycin (Dapto) in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Endocarditis

Sunday, September 13

(Poster Session 082a, 11:15 am – 1:15 pm)

- E-808/275: Activity of Torezolid against linezolid-resistant MRSA strains with *cfr* gene mediated resistance
- E-807/274: Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain
- E-809/276: In Vitro Activity of Torezolid (TR-700) versus Linezolid against Chlamydia species

Monday, September 14

(Poster Session 155, 11:15 am – 1:15 pm)

- C1-1346/84: Unexpectedly low cost of fitness associated with acquisition of the *cfr* resistance gene
- C1-1364b/104: Genetic Environment and Instability of *cfr* in MRSA CM05

- C1-1364a/103: In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial
- C1-1349/87: Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin

Tuesday, September 15

(Poster Session 226, 9:00 am – 11:00 am)

- A1-1939/12: Compararative Pharmacodynamics of a Novel Oxazolidinone, TR-701, Against *S. aureus* in a Neutropenic Murine Pneumonia Infection Model
- A1-1935/8: Defining the Impact of Granulocytes (G) on the Kill of Methicillin-Resistant Staphylococcus aureus (MRSA) by the New Oxazolidanone Prodrug TR-701
- A1-1947/20: Evaluation of Tissue Distribution of TR-700 in Healthy Volunteers, Using Microdialysis
- A1-1934/7: Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid

Copies of these posters will be available on the Trius Web site following the ICAAC meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.

Contact: Jason Spark of Porter Novelli Life Sciences, +1-619-849-6005, jspark@pnlifesciences.com, for Trius Therapeutics, Inc.